Eswatini adopts new two-injection HIV prevention drug
Lenacapavir offers protection through two doses annually, expanding choices for those struggling with daily medication.
Eswatini has become one of the first countries in the region to introduce Lenacapavir, a new long-acting injectable drug for HIV prevention. This medication requires only two injections per year, providing an alternative to daily oral pills. The drug is expected to increase prevention options, especially for adolescent girls and young women who may find daily medication challenging.
UNAIDS Strategic Information Advisor Nsindiso Dlamini highlighted the drug's introduction at the 2026 Regional World AIDS Day Commemoration in the Hhohho Region on Friday, November 6. He stated that Lenacapavir's two-injection schedule could simplify prevention for many. However, Dlamini cautioned that it must be offered alongside existing methods like condoms, oral PrEP, VMMC, and HIV testing.
The introduction of Lenacapavir supports Eswatini's goal to end AIDS as a public health threat by 2030. Dlamini stressed that medical advances must reach those in need and called for continued investment in existing services. He emphasised the importance of community involvement and respecting the privacy of users when shaping HIV prevention programmes.
Why it mattersEswatini residents seeking HIV prevention now have a new option with fewer doses than daily pills.